These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 23548269

  • 1. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.
    Cancer Res; 2013 Jun 15; 73(12):3683-91. PubMed ID: 23548269
    [Abstract] [Full Text] [Related]

  • 2. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
    Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM.
    Mol Pharmacol; 2012 Oct 15; 82(4):767-76. PubMed ID: 22833573
    [Abstract] [Full Text] [Related]

  • 3. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Smith HL, Willmore E, Prendergast L, Curtin NJ.
    Br J Cancer; 2024 Sep 15; 131(5):905-917. PubMed ID: 38965423
    [Abstract] [Full Text] [Related]

  • 4. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P, Gajek A, Marczak A, Mikuła M, Ostrowski J, Śliwińska A, Rogalska A.
    Int J Mol Sci; 2020 Dec 19; 21(24):. PubMed ID: 33352723
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J.
    Int J Clin Oncol; 2017 Aug 19; 22(4):619-628. PubMed ID: 28643177
    [Abstract] [Full Text] [Related]

  • 17. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability.
    Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ.
    Nat Cell Biol; 2007 Apr 19; 9(4):391-401. PubMed ID: 17384638
    [Abstract] [Full Text] [Related]

  • 18. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.
    Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, Lieberman HB, Chen J, Cliby WA, Kaufmann SH.
    Mol Pharmacol; 2005 Dec 19; 68(6):1636-44. PubMed ID: 16126823
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.